BACKGROUND: Ewing sarcoma (ES) is the most common chest wall malignancy in adolescents. Current therapy incorporates chemotherapy to treat systemic disease and radiotherapy to assist with local control. We sought to evaluate the timing of surgery and role of adjuvant radiotherapy. METHODS: We reviewed the St. Jude Children's Research Hospital chest wall ES experience from 1979 to 2009. Patient demographics, tumor characteristics, treatment variables, and outcomes were analyzed with respect to timing of surgery and use of adjuvant radiotherapy. RESULTS: Our cohort consisted of 36 patients with chest wall ES; median follow-up was 14.2 years, and 15-year estimate of overall survival was 66 %. In patients with localized disease, the timing of surgery (up-front vs. delayed) did not impact margin negativity or the use of adjuvant radiotherapy, but it did decrease the extent of chest wall resection. When considering radiotherapy in patients with localized disease, we found that patients who did not receive radiotherapy had smaller tumor size (median 6 vs. 10 cm) (p = 0.04) and were more likely to have had negative margins (p = 0.01) than patients who received adjuvant radiotherapy. One patient in each group developed a locoregional recurrence. The 15-year estimated of overall survival for patients who received adjuvant radiotherapy was 80 versus 100 % for those who did not. CONCLUSIONS: Delayed surgery decreased the extent of chest wall resection and helped define a patient population with favorable tumor biology. Patients with complete pathologic responses to chemotherapy, and those with tumors <8 cm and negative surgical margins may be spared adjuvant radiotherapy without any decrement in overall survival.
BACKGROUND:Ewing sarcoma (ES) is the most common chest wall malignancy in adolescents. Current therapy incorporates chemotherapy to treat systemic disease and radiotherapy to assist with local control. We sought to evaluate the timing of surgery and role of adjuvant radiotherapy. METHODS: We reviewed the St. Jude Children's Research Hospital chest wall ES experience from 1979 to 2009. Patient demographics, tumor characteristics, treatment variables, and outcomes were analyzed with respect to timing of surgery and use of adjuvant radiotherapy. RESULTS: Our cohort consisted of 36 patients with chest wall ES; median follow-up was 14.2 years, and 15-year estimate of overall survival was 66 %. In patients with localized disease, the timing of surgery (up-front vs. delayed) did not impact margin negativity or the use of adjuvant radiotherapy, but it did decrease the extent of chest wall resection. When considering radiotherapy in patients with localized disease, we found that patients who did not receive radiotherapy had smaller tumor size (median 6 vs. 10 cm) (p = 0.04) and were more likely to have had negative margins (p = 0.01) than patients who received adjuvant radiotherapy. One patient in each group developed a locoregional recurrence. The 15-year estimated of overall survival for patients who received adjuvant radiotherapy was 80 versus 100 % for those who did not. CONCLUSIONS: Delayed surgery decreased the extent of chest wall resection and helped define a patient population with favorable tumor biology. Patients with complete pathologic responses to chemotherapy, and those with tumors <8 cm and negative surgical margins may be spared adjuvant radiotherapy without any decrement in overall survival.
Authors: B N Rao; F A Hayes; E I Thompson; A P Kumar; I D Fleming; A A Green; B A Austin; J W Pate; H O Hustu Journal: Ann Thorac Surg Date: 1988-07 Impact factor: 4.330
Authors: B N Rao; F A Hayes; E I Thompson; A P Kumar; I D Fleming; A A Green; B A Austin; J W Pate; H O Hustu Journal: Ann Thorac Surg Date: 1995-11 Impact factor: 4.330
Authors: Matthew J Krasin; Carlos Rodriguez-Galindo; Catherine A Billups; Andrew M Davidoff; Michael D Neel; Thomas E Merchant; Larry E Kun Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-01 Impact factor: 7.038
Authors: Robert C Shamberger; Michael P LaQuaglia; Mark C Gebhardt; James R Neff; Nancy J Tarbell; Karen C Marcus; Scott L Sailer; Richard B Womer; James S Miser; Paul S Dickman; Elizabeth J Perlman; Meenakshi Devidas; Stephen B Linda; Mark D Krailo; Holcombe E Grier; Linda Granowetter Journal: Ann Surg Date: 2003-10 Impact factor: 12.969
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Courtney J Harris; Irene Helenowski; Andrew J Murphy; Sara A Mansfield; Michael P LaQuaglia; Todd E Heaton; Michele Cavalli; Joseph T Murphy; Erika Newman; Richard E Overmen; Tanvi T Kartal; Jo Cooke-Barber; Addison Donaher; Marcus M Malek; Ranjeet Kalsi; Eugene S Kim; Michael J Zobel; Catherine J Goodhue; Bindi J Naik-Mathuria; Imory N Jefferson; Jonathan P Roach; Claudia Mata; Nelson Piché; Shahrzad Joharifard; Serge Sultan; Scott S Short; Rebecka L Meyers; Josh Bleicher; Hau D Le; Kevin Janek; Andreana Bütter; Jacob Davidson; Jennifer H Aldrink; Holden W Richards; Elisabeth T Tracy; Sarah J Commander; Elizabeth A Fialkowski; Misty Troutt; Roshni Dasgupta; Timothy B Lautz Journal: Ann Surg Date: 2020-11-04 Impact factor: 12.969